Coherus Oncology is prioritizing esophageal cancer after eight out of nine evaluable first-line esophageal squamous cell patients responded, an 89% ORR. The company is cutting headcount by 30%, primarily on the non-commercial side. It plans to meet FDA early in 2027 on the recommended phase two dose.
CHRS · Coherus Oncology, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“After considering these plans and the guidance within ASC 205-40, we concluded that substantial doubt about our ability to continue as a going concern had not been alleviated for the one-year period following the issuance of these condensed consolidated financial statements. Our expected future operating losses and negative cash flows, together with our need for additional funding to support planned operations, raise substantial doubt about our ability to continue as a going concern for a period of one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 9, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Coherus Oncology, Inc. is prioritizing esophageal cancer, cutting headcount approximately 30% from about 140 to 100 FTEs and expecting $6 to $7 million per quarter in savings; cash runway remains less than 12 months.
Coherus Oncology reported $83.6 million in cash and marketable securities as of September 30, 2026. Management concluded substantial doubt about the company's ability to continue as a going concern remained, citing expected operating losses, negative cash flows and additional funding needs.
Coherus Oncology prioritized tagmokitug/toripalimab development for esophageal cancer, reduced headcount by ~30%, and reported Q3 2026 LOQTORZI net revenue of $14.0 million. Q3 net loss from continuing operations was $38.9 million, or $(0.25) per diluted share.
Coherus reported interim TREGCHECK data for tagmokitug with toripalimab, with or without chemotherapy, in solid tumors. In evaluable front-line esophageal squamous cell carcinoma patients, the confirmed overall response rate was 75% irrespective of PD-L1 status and 100% in PD-L1 positive patients as of October 14, 2026. The company plans to expand enrollment in first-line and second-line ESCC cohorts.